Publicador de continguts

Recerca

CoViproteHCt

Imatge 3D coronavirus
Foto: Freepik user2109397
Durada
18/4/2020 - 31/12/2021
Coordinador
Technische Universität München
Finançadors
EIT Health

The current restrictions related to SARS-CoV-2 impose a major burden on our healthcare system, society and economy. A significant gap is the lack of test systems to identify people already immune to SARS-CoV-2 and who would thus be protected from re-infection. While development of numerous serological assays is underway worldwide, it remains unknown whether the measured immune responses are truly protective. CoViproteHCt addresses this gap by rapidly developing and validating such urgently needed assays to characterize protective immune responses that can then be used to identify protected individuals, in particular healthcare personnel (HCP) working with COVID-19 patients and in other critical areas. The developed assays can subsequently be adapted by companies and academic partners throughout the world within weeks.
This approach will allow the selective release of HCP from quarantine restrictions and their subsequent return to work, thus stabilizing our healthcare system and economy.

Funding

678.671 €

Our Team

Equip ISGlobal

Altres projectes

INCENTIVE

Indo-European Consortium for Next Generation Influenza Vaccine Innovation

FLAVOBAC

Nuevas moléculas de oro coordinadas con flavonoides contra bacterias patógenas multirresistentes prioritarias

EpiGen

Building Scalable Pathogen Genomic Epidemiology in Ethiopia

ENDÈMIC

Community knowledge generation through scientific culture, urban ecology and art